Diskussion zu CytoSorbents Corporation (Seite 423)
eröffnet am 20.05.09 17:22:57 von
neuester Beitrag 30.05.24 11:48:58 von
neuester Beitrag 30.05.24 11:48:58 von
Beiträge: 4.242
ID: 1.150.520
ID: 1.150.520
Aufrufe heute: 18
Gesamt: 690.752
Gesamt: 690.752
Aktive User: 0
ISIN: US23283X2062 · WKN: A12GDU
0,8210
EUR
+1,55 %
+0,0125 EUR
Letzter Kurs 31.05.24 Quotrix Düsseldorf
Neuigkeiten
| TitelBeiträge |
|---|
09.05.24 · globenewswire  |
02.05.24 · globenewswire |
26.04.24 · globenewswire |
17.04.24 · globenewswire |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4900 | +185,09 | |
| 1,0500 | +128,31 | |
| 0,9899 | +41,41 | |
| 3,3400 | +17,40 | |
| 2,4700 | +14,88 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4350 | -18,47 | |
| 5,5100 | -18,97 | |
| 1,5000 | -25,00 | |
| 0,9000 | -53,85 | |
| 0,6002 | -57,27 |
Beitrag zu dieser Diskussion schreiben
Feedback
Weder findet man bei der FDA noch bei Vivantes etwas über Cytosorb. Du kannst gerne bei den Ärzten und Kliniken anrufen oder ihnen eine eMail schicken und uns dann mitteilen ob Cytosorb existiert.
Ich geb traumstrand recht du schreibst nur Müll , wenn du dir mehr mühe gibst findest du alle Infos ....
Cytosorb könnte zukünftig viele Menschenleben retten wenn die Studie erfolgreich verläuft .
MedaSorb Registers CytoSorbTM Clinical Study
MONMOUTH JUNCTION, NJ--(Marketwire - November 20, 2007) - MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE), a medical device company focused on the development of its platform technology for removal of toxins from blood and physiologic fluids, has registered its CytoSorb™ clinical trial in Germany at the ClinicalTrials.Gov website. ClinicalTrials.Gov is a worldwide registry managed by the National Institutes of Health for government funded or privately supported clinical trials.
"Registering the trial at ClinicalTrials.Gov is another step forward in the launching of our clinical trial in Germany," MedaSorb's CEO, Al Kraus commented. "Registration of the trial will allow the investigators to publish results of the trial in medical journals."
Sepsis is a major cause of mortality, killing 1,400 people worldwide every day. The estimated incidence of sepsis is 1.0 million patients per year in the U.S., with an estimated annual economic cost of $18 billion and approximately 215,000 deaths. It is estimated that Europe has similar statistics.
The CytoSorb™ device is designed to optimize the ability to remove cytokines from the blood stream, restore quality of life and save lives. It is protected by 24 patents with additional patents pending.
The CytoSorb™ medical device offers a promising alternative in removing cytokines, which are believed to be key mediators in the inflammatory and often deadly response of the immune system to sepsis. MedaSorb believes CytoSorb will be clinically effective as an adjunctive therapy in the treatment of sepsis, by reducing the harmful level of cytokines in patients.
Other intended applications include the prevention of post-operative complications of cardiac surgery, prevention of damage to organs donated for transplant prior to organ harvest, short and long-term treatment of kidney failure, and drug detoxification.
About Sepsis
Sepsis is a condition that can result from a person's over-response to infection or injury. Approximately 50% of the 2 million worldwide sepsis cases lead to death and is the second most frequent cause of death in hospitals outside the cardiac ICU. Severe sepsis is often more dangerous than the initial infection and, without rapid diagnosis and intervention, can develop within a matter of hours, leading to septic shock which can cause temporary or permanent damage to multiple organs or even death.
About MedaSorb
MedaSorb Technologies Corporation is a medical device company preparing to commercialize blood purification technology that effectively removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb™ and BetaSorb™, are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey. http://www.medasorb.com/
Ich geb traumstrand recht du schreibst nur Müll , wenn du dir mehr mühe gibst findest du alle Infos ....
Cytosorb könnte zukünftig viele Menschenleben retten wenn die Studie erfolgreich verläuft .
MedaSorb Registers CytoSorbTM Clinical Study
MONMOUTH JUNCTION, NJ--(Marketwire - November 20, 2007) - MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE), a medical device company focused on the development of its platform technology for removal of toxins from blood and physiologic fluids, has registered its CytoSorb™ clinical trial in Germany at the ClinicalTrials.Gov website. ClinicalTrials.Gov is a worldwide registry managed by the National Institutes of Health for government funded or privately supported clinical trials.
"Registering the trial at ClinicalTrials.Gov is another step forward in the launching of our clinical trial in Germany," MedaSorb's CEO, Al Kraus commented. "Registration of the trial will allow the investigators to publish results of the trial in medical journals."
Sepsis is a major cause of mortality, killing 1,400 people worldwide every day. The estimated incidence of sepsis is 1.0 million patients per year in the U.S., with an estimated annual economic cost of $18 billion and approximately 215,000 deaths. It is estimated that Europe has similar statistics.
The CytoSorb™ device is designed to optimize the ability to remove cytokines from the blood stream, restore quality of life and save lives. It is protected by 24 patents with additional patents pending.
The CytoSorb™ medical device offers a promising alternative in removing cytokines, which are believed to be key mediators in the inflammatory and often deadly response of the immune system to sepsis. MedaSorb believes CytoSorb will be clinically effective as an adjunctive therapy in the treatment of sepsis, by reducing the harmful level of cytokines in patients.
Other intended applications include the prevention of post-operative complications of cardiac surgery, prevention of damage to organs donated for transplant prior to organ harvest, short and long-term treatment of kidney failure, and drug detoxification.
About Sepsis
Sepsis is a condition that can result from a person's over-response to infection or injury. Approximately 50% of the 2 million worldwide sepsis cases lead to death and is the second most frequent cause of death in hospitals outside the cardiac ICU. Severe sepsis is often more dangerous than the initial infection and, without rapid diagnosis and intervention, can develop within a matter of hours, leading to septic shock which can cause temporary or permanent damage to multiple organs or even death.
About MedaSorb
MedaSorb Technologies Corporation is a medical device company preparing to commercialize blood purification technology that effectively removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb™ and BetaSorb™, are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. Management believes the potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short- and long-term treatment of kidney failure. MedaSorb is headquartered in Monmouth Junction, New Jersey. http://www.medasorb.com/
Antwort auf Beitrag Nr.: 37.231.780 von traumstrand am 22.05.09 10:58:18Es ist eine ordentliche Anmeldung (und somit Freigabe) des Projektes bei der FDA vorhanden, die Studien laufen in Deutschland - kannst ja mal in #8 nachlesen und ggf. mal in einer der Kliniken anrufen und nachtragen, ob es die Cytosorb gibt...
Weder findet man bei der FDA noch bei Vivantes etwas über Cytosorb. Du kannst gerne bei den Ärzten und Kliniken anrufen oder ihnen eine eMail schicken und uns dann mitteilen ob Cytosorb existiert.
Bilder hast Du außerdem selber aufgetrieben, da weißt Du schon mal ungefähr, wie die Sache aussieht...
Was ist dort zu sehen? Nichts...
Dein Diskussionsniveau ist jedenfalls unterirdisch. Ich respektiere kritische Meinungen sehr - nur deswegen sind Foren wie bei WO für mich sinnvoll. Aber solchen Müll kann ich kaum erstragen. Bin kurz davor, Dich auszublenden.
Wie oft ich das schon gehört habe... am Ende hat nur einer Recht.
Weder findet man bei der FDA noch bei Vivantes etwas über Cytosorb. Du kannst gerne bei den Ärzten und Kliniken anrufen oder ihnen eine eMail schicken und uns dann mitteilen ob Cytosorb existiert.
Bilder hast Du außerdem selber aufgetrieben, da weißt Du schon mal ungefähr, wie die Sache aussieht...
Was ist dort zu sehen? Nichts...
Dein Diskussionsniveau ist jedenfalls unterirdisch. Ich respektiere kritische Meinungen sehr - nur deswegen sind Foren wie bei WO für mich sinnvoll. Aber solchen Müll kann ich kaum erstragen. Bin kurz davor, Dich auszublenden.
Wie oft ich das schon gehört habe... am Ende hat nur einer Recht.
@ Typhoon: Oioioi, Deine Behauptungen sind echt aus der Luft gegriffen. Es ist eine ordentliche Anmeldung (und somit Freigabe) des Projektes bei der FDA vorhanden, die Studien laufen in Deutschland - kannst ja mal in #8 nachlesen und ggf. mal in einer der Kliniken anrufen und nachtragen, ob es die Cytosorb gibt...
Bilder hast Du außerdem selber aufgetrieben, da weißt Du schon mal ungefähr, wie die Sache aussieht...
Dein Diskussionsniveau ist jedenfalls unterirdisch. Ich respektiere kritische Meinungen sehr - nur deswegen sind Foren wie bei WO für mich sinnvoll. Aber solchen Müll kann ich kaum erstragen. Bin kurz davor, Dich auszublenden.
Bilder hast Du außerdem selber aufgetrieben, da weißt Du schon mal ungefähr, wie die Sache aussieht...
Dein Diskussionsniveau ist jedenfalls unterirdisch. Ich respektiere kritische Meinungen sehr - nur deswegen sind Foren wie bei WO für mich sinnvoll. Aber solchen Müll kann ich kaum erstragen. Bin kurz davor, Dich auszublenden.
Antwort auf Beitrag Nr.: 37.230.088 von BrauchGeld am 21.05.09 22:49:33Bei 3$ hätte ich niemals die Aktie gekauft aber ich bin bei 7 cent eingestiegen um bei 3$ verkaufen zu können.
Gerade das ist schwachsinnig!
Bei der Story muss man am ersten Tag investiert sein und wenns nicht steil bergauf geht ist die Story nichts wert. Die eine hälfte habe ich bei ca. 4$ verkauft die andere bei ca. 2$, also habe ich hier weder etwas gewonnen noch etwas verloren.
Medasorb schließt im grünen Bereich unter Rekordvolumen !
Hast du deine Eigentumswohnung verkauft und alles auf MSBT gesetzt?
Gerade das ist schwachsinnig!
Bei der Story muss man am ersten Tag investiert sein und wenns nicht steil bergauf geht ist die Story nichts wert. Die eine hälfte habe ich bei ca. 4$ verkauft die andere bei ca. 2$, also habe ich hier weder etwas gewonnen noch etwas verloren.
Medasorb schließt im grünen Bereich unter Rekordvolumen !
Hast du deine Eigentumswohnung verkauft und alles auf MSBT gesetzt?
Das Medasorb nicht so bekannt ist sieht man auch daran das trotz dieser Nachricht den Hype nicht mitgemacht hat ..
CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak
Wednesday May 6, 2009, 8:30 am EDT
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--May 6, 2009 -- CytoSorbents, Inc. comments on the current swine flu outbreak and highlights the urgent need for improved therapies for influenza and other respiratory viruses. In particular, potentially virulent pathogens such as avian flu (H5N1 subtype), swine flu (H1N1 subtype), and the SARS virus can quickly kill a large percentage of those infected. According to the Centers for Disease Control, normal seasonal influenza afflicts 15-60 million people in the United States each year, hospitalizing more than 200,000, and directly contributing to the deaths of 36,000 people annually. Although these numbers are significant, in contrast, the 1918 Spanish influenza pandemic infected an estimated one third of the world population, killing nearly 50 million people. Highly virulent flu strains have the ability to evade neutralization by the immune system, leading to a prolonged and intense infection that can lead to severe sepsis and death. Although the virus itself has destructive capability, the body's own aggressive immune response and "cytokine storm" are recognized as leading drivers of mortality in these patients. Cytokines are normally helpful proteins that control the immune system. In severe sepsis due to influenza, however, cytokines are often produced in excessive, toxic quantities leading to acute respiratory distress syndrome (severe lung inflammation), organ failure, and numerous complications that often result in death. Anti-viral therapy such as Tamiflu(TM), Relenza(TM) and amantadine may slow viral infection if used early enough and if resistance is not an issue. But given the major role that cytokine storm is believed to play in the pathogenesis of these deadly viruses, more options are needed to directly address this critical issue now.
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments. In animal bacterial sepsis studies performed at the University of Pittsburgh Medical Center, CytoSorb(TM) significantly improved hemodynamic stability and short-term survival while simultaneously reducing cytokine levels with a single treatment, compared to sham-treated control animals. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. All of these patients are on mechanical ventilation and have either acute lung injury or acute respiratory distress syndrome, similar to what is expected to be seen in a major influenza pandemic. The results from this study may pave the way for the potential future use of CytoSorb(TM) in the treatment of critically ill influenza patients.
CytoSorbents Chief Executive Officer, Phillip Chan, MD, PhD, stated, "It has been well-accepted that severe sepsis, caused by either bacteria or viruses, has two important facets. One is the infectious agent that can be treated with antibiotics or antiviral medications. But the other is the body's unregulated immune system and cytokine storm that causes much of the organ damage and death in patients with sepsis. Little exists to treat this major problem. CytoSorb(TM) is a powerful technology that could fill this gap."
Dr. Chan continued, "The alarm raised by the current swine flu outbreak demonstrates how vulnerable we are to medical emergencies such as these, be they natural or man-made. In particular, it has highlighted a key weakness in our armamentarium to treat severe infection -- the inability to effectively address cytokine storm. Although CytoSorb(TM) is currently an investigational device and its applicability in influenza remains to be seen, it has the clear potential to be a leading therapy to treat cytokine storm and make a real difference in getting patients well."
Tamiflu(TM) and Relenza(TM) are trademarks of Roche Holding AG and GlaxoSmithKline plc, respectively
CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak
Wednesday May 6, 2009, 8:30 am EDT
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--May 6, 2009 -- CytoSorbents, Inc. comments on the current swine flu outbreak and highlights the urgent need for improved therapies for influenza and other respiratory viruses. In particular, potentially virulent pathogens such as avian flu (H5N1 subtype), swine flu (H1N1 subtype), and the SARS virus can quickly kill a large percentage of those infected. According to the Centers for Disease Control, normal seasonal influenza afflicts 15-60 million people in the United States each year, hospitalizing more than 200,000, and directly contributing to the deaths of 36,000 people annually. Although these numbers are significant, in contrast, the 1918 Spanish influenza pandemic infected an estimated one third of the world population, killing nearly 50 million people. Highly virulent flu strains have the ability to evade neutralization by the immune system, leading to a prolonged and intense infection that can lead to severe sepsis and death. Although the virus itself has destructive capability, the body's own aggressive immune response and "cytokine storm" are recognized as leading drivers of mortality in these patients. Cytokines are normally helpful proteins that control the immune system. In severe sepsis due to influenza, however, cytokines are often produced in excessive, toxic quantities leading to acute respiratory distress syndrome (severe lung inflammation), organ failure, and numerous complications that often result in death. Anti-viral therapy such as Tamiflu(TM), Relenza(TM) and amantadine may slow viral infection if used early enough and if resistance is not an issue. But given the major role that cytokine storm is believed to play in the pathogenesis of these deadly viruses, more options are needed to directly address this critical issue now.
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments. In animal bacterial sepsis studies performed at the University of Pittsburgh Medical Center, CytoSorb(TM) significantly improved hemodynamic stability and short-term survival while simultaneously reducing cytokine levels with a single treatment, compared to sham-treated control animals. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. All of these patients are on mechanical ventilation and have either acute lung injury or acute respiratory distress syndrome, similar to what is expected to be seen in a major influenza pandemic. The results from this study may pave the way for the potential future use of CytoSorb(TM) in the treatment of critically ill influenza patients.
CytoSorbents Chief Executive Officer, Phillip Chan, MD, PhD, stated, "It has been well-accepted that severe sepsis, caused by either bacteria or viruses, has two important facets. One is the infectious agent that can be treated with antibiotics or antiviral medications. But the other is the body's unregulated immune system and cytokine storm that causes much of the organ damage and death in patients with sepsis. Little exists to treat this major problem. CytoSorb(TM) is a powerful technology that could fill this gap."
Dr. Chan continued, "The alarm raised by the current swine flu outbreak demonstrates how vulnerable we are to medical emergencies such as these, be they natural or man-made. In particular, it has highlighted a key weakness in our armamentarium to treat severe infection -- the inability to effectively address cytokine storm. Although CytoSorb(TM) is currently an investigational device and its applicability in influenza remains to be seen, it has the clear potential to be a leading therapy to treat cytokine storm and make a real difference in getting patients well."
Tamiflu(TM) and Relenza(TM) are trademarks of Roche Holding AG and GlaxoSmithKline plc, respectively
Trading Spotlight
Antwort auf Beitrag Nr.: 37.229.446 von TyphoonRally am 21.05.09 21:29:03@TR
Du schreibst so einen Schwachsinn hast du etwa viel geld mit MSBT verloren ?
Bei 3$ hätte ich niemals die Aktie gekauft aber ich bin bei 7 cent eingestiegen um bei 3$ verkaufen zu können
.
..
Medasorb schließt im grünen Bereich unter Rekordvolumen !
Du schreibst so einen Schwachsinn hast du etwa viel geld mit MSBT verloren ?
Bei 3$ hätte ich niemals die Aktie gekauft aber ich bin bei 7 cent eingestiegen um bei 3$ verkaufen zu können
...
Medasorb schließt im grünen Bereich unter Rekordvolumen !
Antwort auf Beitrag Nr.: 37.229.087 von traumstrand am 21.05.09 20:43:27Das Cytosorb kann garnicht funktionieren, weil es nicht existiert. Würde es existieren, dann hätte man es uns längst präsentiert.
Eine von vielen OTC-Klitschen die langfristig bei 0,0001 enden.
Die Aktie ist innerhalb von 3 Jahren von 3$ auf 0,03$ Gefallen... 2012 ist die Aktie wahrscheinlich nur noch 0,0003-0,0001 wert. Es ist einfach nichts dran an der Story.
Eine von vielen OTC-Klitschen die langfristig bei 0,0001 enden.
Die Aktie ist innerhalb von 3 Jahren von 3$ auf 0,03$ Gefallen... 2012 ist die Aktie wahrscheinlich nur noch 0,0003-0,0001 wert. Es ist einfach nichts dran an der Story.
Antwort auf Beitrag Nr.: 37.225.378 von TyphoonRally am 21.05.09 11:07:46@ Typhoon: Das Posting ist Blödsinn!
Das Cytosorb funktioniert im Prinzip eher wie ein Dialysegerät, nur daß damit nicht Nierengifte ausgewaschen werden, sondern die Zytokine, die die Sepsis verschlimmern sollen. Wenn Du Bilder vergleichen willst, such mal nach "Dialysemembrane" z.B. von FMC.
Das Cytosorb funktioniert im Prinzip eher wie ein Dialysegerät, nur daß damit nicht Nierengifte ausgewaschen werden, sondern die Zytokine, die die Sepsis verschlimmern sollen. Wenn Du Bilder vergleichen willst, such mal nach "Dialysemembrane" z.B. von FMC.
Hier wird der vorgang etwas näher erklärt ..
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments.
CytoSorbents, Inc. and its parent, MedaSorb Technologies Corporation (OTC BB:MSBT.OB - News), have developed CytoSorb(TM), a highly-porous polymer resin that acts as a cytokine filter and can broadly remove cytokines from blood to potentially treat cytokine storm. Treatment is straightforward. A patient's blood is pumped through a CytoSorb(TM) cartridge where cytokines and toxins are adsorbed and removed by the resin. Treated blood is then returned to the patient. This highly efficient blood purification device has demonstrated the ability to remove up to 90% of certain cytokines from blood within a single treatment period during in vitro blood circulation experiments.
Antwort auf Beitrag Nr.: 37.223.943 von traumstrand am 20.05.09 23:51:14Von Milliardenmarkt für diese spezielle Anwendung würde ich nicht unbedingt sprechen. Z.B. gibt es das Spezialmedikament "XIGRIS" von Lilly, das kostet pro Anwendung locker 20.000 €, scheint relativ gut zu funktionieren und hat definitiv deutlich weniger als 500 Mio USD Jahresumsatz weltweit (genauer Zahlen konnte ich nicht finden, könnten vielleicht auch nur 50 Mio. sein...).
Xigris ist ein Flop und zwar deshalb weil es nur bei bestimmten Sepsis kranken eingesetzt werden darf , außerdem waren die PIII Daten damals nicht gerade überzeugend demnach ist Xigris nur minimal besser als Placebo und deshalb sein geld nicht wert .
Bei Cytosorb handelt es sich um ein art "Filter" um es vereinfacht auszudrücken und ich finde die Technik dahinter sehr interessant .
Xigris ist ein Flop und zwar deshalb weil es nur bei bestimmten Sepsis kranken eingesetzt werden darf , außerdem waren die PIII Daten damals nicht gerade überzeugend demnach ist Xigris nur minimal besser als Placebo und deshalb sein geld nicht wert .
Bei Cytosorb handelt es sich um ein art "Filter" um es vereinfacht auszudrücken und ich finde die Technik dahinter sehr interessant .
Durchsuchen
